A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) | MicrobiomeTrials
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-04-08Est. Completion: 2023-07-17
Enrollment target: 66 participants
Locations
Aichi Cancer Center Hospital ( Site 1013), Nagoya, Aichi-ken, Japan
Nagoya University Hospital ( Site 1021), Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East ( Site 1002), Kashiwa, Chiba, Japan
National Hospital Organization Shikoku Cancer Center ( Site 1014), Matsuyama, Ehime, Japan
National Hospital Organization Hokkaido Cancer Center ( Site 1017), Sapporo, Hokkaido, Japan
Hokkaido University Hospital ( Site 1022), Sapporo, Hokkaido, Japan
Hyogo Cancer Center ( Site 1005), Akashi, Hyōgo, Japan
Hyogo College of Medicine Hospital ( Site 1019), Nishinomiya, Hyōgo, Japan
University of Tsukuba Hospital ( Site 1020), Tsukuba, Ibaraki, Japan
Kanagawa Cancer Center ( Site 1010), Yokohama, Kanagawa, Japan
Medical Corporation Nahanishikai Nahanishi Clinic ( Site 1016), Naha, Okinawa, Japan
Saitama Cancer Center ( Site 1018), Kitaadachi-gun, Saitama, Japan
National Hospital Organization Kyushu Cancer Center ( Site 1009), Fukuoka, Japan
Fukushima Medical University Hospital ( Site 1012), Fukushima, Japan
Hiroshima City Hiroshima Citizens Hospital ( Site 1024), Hiroshima, Japan
Other microbiome trials you might be interested in